Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients

Comparison of Efficacy and Ocular Surface Disease Assessment Between Monoprost and BAK-preserved Latanoprost in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Study

Not provided

Inclusion Criteria:

• IOP >/= 15mmHg and < 40 mmHg in each eye using Goldmann applanation tonometry at visit 2
• Written consent voluntarily to participate in this clinical trial

Exclusion Criteria:

• Patients with closed-angle, congenital glaucoma or secondary glaucoma caused by steroid drugs, etc.
• best-corrected visual acuity 20/80 or less
• Patients who have ongoing medical history of ocular inflammation
• central corneal thickness is not in between 470um and 591um.
• Patients who have received lacrimal duct procedure within the last 3 months or who have plans to have it.
• pregnant or nursing women